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Mantle cell lymphoma (MCL) is a mature, aggressive
B cell lymphoma that usually presents at an advanced
stage, with frequent involvement of the peripheral
blood (PB) [1,2]. MCL is the most common lymphoma
presenting as multiple lymphomatous polyposis of the
intestine [3–6]. The neoplastic cells of MCL express
CD5, CD20 and CD43, but not CD23 or myeloid anti-
gens [2,7]. In patients with a prior history of MCL, the
appearance of leukemic cells usually heralds a relapse,
particularly if the leukemic cells express antigens in
common with the initial neoplastic cells. CD19 is a
membrane protein expressed in B cell neoplasms and
in a subset of acute myeloid leukemias (AMLs) [8–10]
while CD43 is a leukocyte-specific surface molecule
expressed in a variety of hematopoietic cells [11–13].
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Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma with frequent involvement of the
gastrointestinal tract and peripheral blood (PB). In addition to the B cell markers, the neoplastic cells
express CD5 and CD43. In patients with a prior history of MCL with PB involvement, the appear-
ance of leukemic cells after chemotherapy usually heralds a relapse, particularly if the leukemic cells
express B cell markers and CD43. We report a patient with MCL who presented with multiple
lymphomatous polyposis of the intestine. The staging procedures revealed the involvement of
lymph nodes, bone marrow and PB. Three years after chemotherapy, thrombocytopenia with the
appearance of rare leukemic cells in the PB was noted. Leukemic cells obtained from bone marrow
aspirate expressed CD19 and CD43, suggesting a relapse. Detailed cytomorphological and immuno-
phenotypic studies unveiled the myeloid nature of these leukemic cells, and a diagnosis of therapy-
related acute myeloid leukemia was made. This case illustrates the importance of morphologic
examination and performing a complete antibody panel in the diagnosis of a suspected relapse in
patients with a prior history of lymphoma.
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Here, we report a patient who had received combi-
nation chemotherapy for MCL and achieved complete
remission. Three years later, leukemic cells appeared
in the PB, and a relapsed MCL was suspected. Interest-
ingly, flow cytometric immunophenotyping revealed
that these leukemic cells expressed CD19 and CD43,
but not CD5 or CD20. Further studies revealed the
myeloid characteristics of these leukemic cells, indicat-
ing therapy-related acute myeloid leukemia (t-AML).
This case illustrates the importance of morphologic
examination and detailed immunophenotyping in the
diagnosis of hematologic neoplasms.
CASE PRESENTATION
Clinical history
A 52-year-old male presented with small intestinal
intussusception and underwent segmental resection
in March 2005. Peripheral blood involvement (white
blood cell [WBC] count, 19.4 × 103/μL; 74% lym-
phocytes) was noted at the time and a mature B cell 
lymphoma was confirmed by flow cytometric immu-
nophenotyping. Biopsies of the left inguinal lymph
node and bone marrow revealed involvement of lym-
phoma. Because of the diagnosis of stage IV disease,
the patient received four courses of chemotherapy with
hyperCVAD (cyclophosphamide, vincristine, doxoru-
bicin, dexamethasone, cytarabine and methotrexate)
from March to October, 2005, and achieved complete
remission. However, thrombocytopenia appeared in
late May 2008 (hemoglobin, 12.2 g/dL; WBC count,
3.4 × 103/μL; platelet count, 78 × 103/μL), 37 months
after chemotherapy. The platelet count further de-
creased to 19 × 103/μL with appearance of rare blasts
in early July 2008 (WBC count, 3.4 × 103/μL; blasts,
2%; platelet count, 19 × 103/μL). To confirm the diag-
nosis of recurrent MCL, bone marrow aspiration 
and biopsy were performed.
Pathology and flow cytometric findings
The resected small intestine was 15 cm long, and five
larger polyps (up to 2 cm in diameter) and numerous
smaller polyps were identified in the segment.
Microscopically, the tumor cells in the intestine were
intermediate in size with moderate nuclear pleomor-
phism, irregular nuclear contours, and inconspicuous
nucleoli. Immunophenotypically, these lymphoma
cells expressed CD5, CD20, CD43, IgD, IgM, bcl-2
and cyclin D1, but did not express CD3, CD10, CD23
or bcl-6. The proliferation index, as determined by
Ki-67 staining, was 20%. Two of the three mesenteric
lymph nodes were involved by lymphoma. Biopsy 
of the left inguinal lymph node revealed total archi-
tectural effacement with a nodular growth pattern.
The tumor cells were identical to those in the small
intestinal tumor in terms of histopathology and im-
munophenotype. The PB lymphoma cells, at presen-
tation in March 2005, were small to medium-sized
atypical lymphocytes with a dense chromatin pattern
and irregular nuclear contours (so-called buttock
cells) (Figure A). Flow cytometric immunophenotyp-
ing showed that these leukemic cells expressed CD5,
CD19, CD20, CD38 and CD43 with a monotypic
expression of surface kappa light chain. They were
negative for CD10, CD13, CD23, CD33, CD34, CD117
and lambda light chain. Therefore, diagnosis of a
stage IV MCL with PB involvement was made.
Three years later, in July 2008, leukemic cells
appeared in the PB and relapsed MCL was suspected.
Microscopically, these leukemic cells were medium-
sized with a fine chromatin pattern and one-to-two
nucleoli (Figure B). The percentage of blasts in the
bone marrow was 61%, with maturation of myeloid
cells. Flow cytometry immunophenotyping of these
blasts revealed expression of CD19 and CD43, but not
CD5 or CD20. Because the chromatin pattern of these
blasts was fine, blastoid transformation of MCL or
therapy-related acute leukemia was suspected. Addi-
tional immunophenotyping revealed that these blasts
expressed CD13, CD33, CD34 (subset), HLA-DR,
CD117 and cytoplasmic myeloperoxidase. Cytochemi-
cal staining of the bone marrow aspirate showed that
the blasts were positive for myeloperoxidase but neg-
ative for nonspecific esterase. A cytogenetic study
revealed 45,X, t(1;3)(q21;p21), der(7)t(5;7)(q22;p22)
[cp8]/45-46; XY [cp12]. These findings confirmed the
diagnosis of AML and excluded the differential diag-
nosis of recurrent MCL.
DISCUSSION
Flow cytometry is a very useful tool for immunophe-
notyping. However, an incomplete antibody panel
might lead to confusing data and erroneous diagno-
sis. In our case, because of the presence of leukemic
cells expressing CD19 and CD43 and the patient’s
CD19/CD43+ blasts after chemotherapy for MCL
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Figure. (A) Mantle cell lymphoma of the small intestine at diagnosis in March 2005 shows multiple lymphomatous polyposes.
Microscopically, the lymphoma cells are medium-sized with moderate pleomorphism and irregular nuclear contours (hematoxylin &
eosin stain). Immunohistochemically, the tumor cells express cyclin D1. The lymphoma cells in the peripheral blood (PB) exhibit irreg-
ular nuclear contours and condensed chromatin (so-called buttock cells). Flow cytometric immunophenotyping of the leukemic cells in
the PB revealed expression of CD5, CD19, CD20 and CD43, but not CD23. (B) Therapy-related acute myeloid leukemia diagnosed in
July 2008. The leukemic cells in the PB and bone marrow exhibit a fine chromatin pattern and nucleoli, and are positive for myeloper-
oxidase by cytochemical stain. Flow cytometry shows that, in addition to CD19 and CD43, the leukemic cells express CD13, CD33,
CD34 (subset), CD117 and cytoplasmic myeloperoxidase, but not CD5 or CD20.
history of MCL, recurrent MCL is a reasonable diagno-
sis. However, the absence of CD5 and CD20 expres-
sion strongly argues against this diagnosis because
the tumor cells in cases of MCL are mature B cells that
express CD20 and the majority of them express CD5.
After re-evaluation of the cellular morphology (fine
chromatin pattern with nucleoli) and the addition of
a myeloid panel, we determined that the leukemic
cells expressed myeloid makers (CD13, CD33, and
myeloperoxidase), CD34, CD117 and HLA-DR and
confirmed the myeloid characteristics of these leukemic
cells.
CD19 is a 95-kDa glycosylated, type I integral
membrane protein and is expressed by mature and
immature B cell neoplasms, benign plasma cells, very
rare plasma cell neoplasms and a subset of AML,
which is usually associated with t(8;21) [8–10]. In our
previous study of AML in Taiwan, the blasts in five
(4.5%) of 111 cases expressed CD19 [14]. All five CD19-
positive tumors were classified as FAB AML-M2, and
four carried chromosomal translocation t(8;21). The 
t-AML in this current case was also classified as
AML-M2, but without t(8;21).
CD43 is a leukocyte-specific surface molecule,
which plays an important role in both cell adhesion
and signal transduction. It is expressed in virtually
all cases of mature T cell and NK cell lymphoma, the
majority of MCLs, small lymphocytic lymphoma/
chronic lymphocytic leukemia (SLL/CLL), acute leu-
kemia (myeloid and lymphoid), myeloid sarcoma and
mast cell neoplasm, and by 50% of plasma cell neo-
plasms [11–13]. CD43 is most useful in the differ-
ential diagnoses of small B cell lymphoproliferative
disorders including SLL/CLL, MCL, marginal zone
lymphoma and follicular lymphoma. Because CD43
is rarely expressed in non-hematopoietic neoplasms,
it is also useful in differentiating between undiffer-
entiated or anaplastic malignancies (hematopoietic
versus non-hematopoietic) [10]. However, because 
of its frequent expression in various types of hemato-
poietic neoplasms, CD43 is not lineage-specific and is
not included in the routine antibody panels for the
immunophenotyping of AML [8,9].
Secondary AML or t-AML arises as a late compli-
cation of cytotoxic chemotherapy and/or radiation
therapy [15]. Although these patients may be diag-
nosed morphologically as therapy-related myelodys-
plastic syndrome (t-MDS), t-AML or t-MDS and
myeloproliferative neoplasms (t-MDS/MPN), all of
these therapy-related neoplasms should be consid-
ered together as a unique clinical syndrome [15]. Two
sets of t-AML/t-MDS and t-MDS/MPN are generally
recognized by the causative agents [15]. The most
common category that occurs 5–10 years after expo-
sure to alkylating agent/radiation is commonly asso-
ciated with unbalanced loss of genetic materials, often
involving chromosome 5 and/or 7. The less common
category, which affects approximately 20–30% of cases,
occurs 1–5 years after exposure to a topoisomerase II
inhibitor and is often associated with balanced chro-
mosomal translocation. However, in practice, many
patients have received polychemotherapy that includes
both classes of drugs and the boundary between the
two categories is blurred. For example, our patient
had been treated with both an alkylating agent
(cyclophosphamide) and a topoisomerase II inhibitor
(doxorubicin). The relatively short interval (3 years)
for developing t-AML was in favor of the effects of
the topoisomerase II inhibitor, while the cytogenetic
findings with aberrations involving chromosomes 5
and 7 were consistent with those of an alkylating agent.
This is an example of the blurred boundary between
the two categories of causative agents for therapy-
related myeloid neoplasms. In conclusion, this case
illustrates the importance of morphologic examina-
tion and performing a complete antibody panel in the
diagnosis of a suspected relapse in patients with a prior
history of hematopoietic neoplasms.
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有套細胞淋巴瘤病史的病人得到化療相關性急性骨
髓性白血病於週邊血液出現同時表現 CD19 
及 CD43 的血癌細胞
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套細胞淋巴癌是一種惡性度高的 B 細胞淋巴瘤。此種淋巴瘤容易侵犯到消化道及週邊
血液。除 B 細胞標記外，這些淋巴瘤細胞同時也表現 CD5 及 CD43。若病人有套細
胞瘤侵犯週邊血液的病史，化療之後週邊血液再度出現不正常的白血球，通常意味著
淋巴瘤復發，尤其是當這些不正常白血球細胞同時表現 B 細胞標記及 CD43 時。在此
我們報告一例腸胃道套細胞淋巴瘤的病例。此病人除腸道外，淋巴結，骨髓及週邊血
液也受到淋巴瘤侵犯。在化療後 3 年，此病人有血小板低下的情形產生，並且在週邊
血液中出現不正常白血球。另外病人的骨髓中也出現不正常的白血球，這些白血球同
時表現 CD19 及 CD43，極可能意味著疾病的復發。但進一步的形態學檢查及流體細
胞計數儀免疫型分析，卻有不同的發現。最後我們診斷為化療引起的急性骨髓性白血
病。這一例特殊病例告訴我們在遇到具有淋巴瘤病史的病人時，完整形態學及免疫型
分析可以幫助我們鑑別是為疾病復發或是另一個疾病的產生。
關鍵詞：CD19，CD43，流體細胞計數儀，套細胞淋巴癌，治療相關性急性骨髓性白血病
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